MAFLD高危人群的筛查和分层管理*

doi:10.3969/j.issn.1672-5069.2023.04.003

Abstract

Zhang Huai, Zheng Minghua. Screening and management of patients with metabolic dysfunction-associated fatty liver disease in high-risk populations[J]. Journal of Practical Hepatology, 2023, 26(4): 463-465.

References

[1] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73 (1): 202-209.
[2] Zhang H, Rios RS, Boursier J, et al. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. Chin Med J (Engl),2023,136(3):341-350.
[3] European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol,2016, 64 (6): 1388-1402.
[4] Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and Meta-analysis. Gastroenterology, 2020, 158 (6): 1611-1625.
[5] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol, 2019, 70 (1): 151-171.
[6] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004,40 (6): 1387-1395.
[7] Kanwal F, Kramer JR, Duan Z, et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol, 2016,14 (2): 301-308,e301-302.
[8] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64 (1): 73-84.
[9] Beste LA, Leipertz SL, Green PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology, 2015, 149 (6): 1471-1482,e1475,quiz e1417-1478.
[10] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380 (9859): 2095-2128.
[11] Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med, 2014,(12): 145.
[12] Mokdad AH, Forouzanfar MH, Daoud F, et al. Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2016, 387 (10036): 2383-2401.
[13] Kanwal F, Kramer JR, Li L, Dai J, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology, 2020, 71 (3): 808-819.
[14] NCD Risk Factor Collaboration. Rigorous and timely data on major risk factors for non-communicable diseases for all of the world's countries. 2023-2-29. (Accessed at https://www.ncdrisc.org/index.html).
[15] Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology,2021,161 (5): 1657-1669.
[16] Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: The need for systematic screening. Diabetes Care, 2021, 44 (2): 399-406.
[17] Noureddin M, Jones C, Alkhouri N, et al. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: A comprehensive cost-utility analysis. Gastroenterology, 2020, 159 (5): 1985-1987,e1984.
[18] Wright AP, Desai AP, Bajpai S, et al. Gaps in recognition and evaluation of incidentally identified hepatic steatosis. Dig Dis Sci, 2015, 60 (2): 333-338.
[19] Natarajan Y, Kramer JR, Yu X, et al. Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes. Hepatology, 2020, 72 (4): 1242-1252.
[20] Wu XX, Zheng KI, Boursier J, et al. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. E Clin Med,2021,41:101145.
[21] Tang LJ, Li G, Eslam M, et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hepatol Int, 2023, 17 (1): 190-201.
[22] Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol, 2019, 17 (9): 1877-1885,e1875.
[23] Feng G, Zhang X, Zhang L, et al. Novel urinary protein panels for the non-invasive diagnosis of non-alcoholic fatty liver disease and fibrosis stages. Liver Int, 2023,43(6):1234-1246.
[24] Canivet CM, Zheng MH, Qadri S, et al. Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic NASH: an international study with 1924 patients. Clin Gastroenterol Hepatol, 2023[ahead of print].
[25] Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut, 2021, 70 (7): 1375-1382.
[26] Chuah KH, Wan Yusoff WNI, Sthaneshwar P, et al. MACK-3 (combination of HOMA, AST and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis. Liver Int, 2019, 39 (7): 1315-1324.
[27] Greenhill C. Diagnosis: new noninvasive test to diagnose NASH by analysing exhaled breath. Nat Rev Gastroenterol Hepatol, 2013, 10 (1): 4.
[28] Sinha R, Lockman KA, Homer NZM, et al. Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease. JHEP Rep, 2020, 2 (5): 100137.
[29] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156 (6): 1717-1730.
[30] Zhou YJ, Gao F, Liu WY, et al. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther, 2021, 54 (4): 470-480.
[31] Cassinotto C, Lapuyade B, Guiu B, et al. Agreement between 2-dimensional shear wave and transient elastography values for diagnosis of advanced chronic liver disease. Clin Gastroenterol Hepatol, 2020, 18 (13): 2971-2979,e2973.
[32] Lefebvre T, Wartelle-Bladou C, Wong P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. Eur Radiol, 2019, 29 (12): 6477-6488.
[33] Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology, 2010, 51 (1): 121-129.
[34] Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis, 2019, 15 (12): 2123-2130.
[35] Panunzi S, Maltese S, Verrastro O, et al. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes Metab, 2021, 23 (4): 980-990.

Screening and management of patients with metabolic dysfunction-associated fatty liver disease in high-risk populations

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gu Qi, Rui Fajuan, Ni Qianqian, et al. Chronic disease management in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 457-459.
[2]	He Fangping. Practice of chronic disease management: What we should do in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 460-462.
[3]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.
[4]	Fu Xin, Liu Yue, Peng Xin, et al.. Screening of occult hepatitis B viral infection in unpaid blood donors with low-level viremia by serum HBV DNA precise detection technology [J]. Journal of Practical Hepatology, 2023, 26(2): 169-172.
[5]	Wu Peng, Gao Liucun, Tang Shanhong. Artificial intelligence in the diagnosis and treatment of patients with liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 293-296.
[6]	Chinese Society of Hepatology, Chinese Society of Gastroenterology, and Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the Management of EVB in Cirrhotic Portal Hypertension [J]. Journal of Practical Hepatology, 2023, 26(2): 0-S4.
[7]	Han Fang, Li Jiazheng, Nan Yuemin. Management of acute kidney injury in patients with livercirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 768-771.
[8]	Liu Lin, Hu Yun, Xu Lan. Lifestyle management of individuals with glucose and lipid metabolism disorders- related diseases [J]. Journal of Practical Hepatology, 2022, 25(4): 464-467.
[9]	Yang Ruixu, Fan Jiangao. Epidemiology and screening of nonalcoholic fatty liver disease-related hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(2): 153-156.
[10]	Qu Ying, Cai Xiaobo, Zhang Qidi, et al. Prevalence of serum anti-mitochondrial antibody-M2 antibody in health check-up individuals [J]. Journal of Practical Hepatology, 2022, 25(2): 203-206.
[11]	Expert Group for Project of Hepatocellular Carcinoma Screening and Surveillance, Chinese Foundation for Hepatitis Prevention and Control. Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection [J]. Journal of Practical Hepatology, 2021, 24(6): 776-785.
[12]	Huang Feihu, Xue Jianya, Zhu Yongmei, et al. Short-term efficacy of sofosbuvir and velpatasvir in the treatment of patients with hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(6): 819-822.
[13]	Zhuge Yuzheng, Wang Xuan. Hepatic sinusoidal obstruction syndrome associated with pyrrolizidine alkaloids [J]. Journal of Practical Hepatology, 2021, 24(5): 617-620.
[14]	Wang Qixia, Ma Xiong. Insights to precision medicine and clinical translational research in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2021, 24(4): 457-459.
[15]	Tian Anran, Xu Ruirui, Hu Pingping, et al. Establishment of a cell model for screening human EFTUD2 gene-targeting small molecule compounds [J]. Journal of Practical Hepatology, 2021, 24(4): 472-475.